Activation of group VI phospholipase A 2 isoforms in cardiac endothelial cells

American Journal of Physiology - Cell Physiology

Volumn 300, Issue 4, 2011, Pages

  Sharma, Janhavi ^a   Turk, John ^b   Mancuso, David J ^b,c   Sims, Harold F ^b,c   Gross, Richard W ^b,c   McHowat, Jane ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Endothelium; Platelet activating factor; Prostacyclin

Indexed keywords

ARACHIDONIC ACID; BROMOENOL LACTONE; PHOSPHOLIPASE A2 GROUP IV; PHOSPHOLIPID; PROSTACYCLIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; TRYPTASE;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HEART; HUMAN; HUMAN CELL; INFLAMMATION; KNOCKOUT MOUSE; MALE; METABOLITE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ARACHIDONIC ACID; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EPOPROSTENOL; GROUP VI PHOSPHOLIPASES A2; HUMANS; ISOENZYMES; MICE; MICE, KNOCKOUT;

MUS;

EID: 79955130117     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00289.2010     Document Type: Article

References (30)

1. Bäck M. Inflammatory signaling through leukotriene receptors in atherosclerosis. Curr Atheroscler Rep 10: 244-251, 2008.
2. 2 enzymes from P388D1 macrophages and Chinese hamster ovary cells. J Biol Chem 272: 8576-8580, 1997.
3. 2 produce spermatozoa with impaired motility and have greatly reduced fertility. J Biol Chem 279: 38194-38200, 2004.
4. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endotheliumdependent responses. Pflügers Arch 459: 881-895, 2010.
5. Dietrich HH, Abendschein DR, Moon SH, Nayeb-Hashemi N, Mancuso DJ, Jenkins CM, Kaltenbronn KM, Blumer KJ, Turk J, Gross RW. Genetic ablation of calcium-independent phospholipase A2_ causes hypercontractility and markedly attenuates endothelium-dependent relaxation to acetylcholine. Am J Physiol Heart Circ Physiol 298: H2208-H2220, 2010.
6. 2. J Biol Chem 266: 7227-7232, 1991.
7. 2s. J Biol Chem 277: 32807-32814, 2002.
8. Kell PJ, Creer MH, Crown KN, Wirsig K, McHowat J. Inhibition of platelet-activating factor (PAF) acetylhydrolase by methyl arachidonyl fluorophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells. J Pharmacol Exp Ther 307: 1163-1170, 2003.
9. 2 and their effect on enzyme activity. J Biol Chem 273: 207-214, 1998.
10. Ma Z, Ramanadham S, Kempe K, Chi XS, Ladenson J, Turk J. Pancreatic islets express a Ca2_-independent phospholipase A2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. J Biol Chem 272: 11118-11127, 1997.
11. 2β. J Biol Chem 276: 13198-13208, 2001.
12. 2γ leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. J Biol Chem 282: 34611-34622, 2007.
13. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 80: 1669-1699, 2000.
14. 2β. J Biol Chem 283: 33975-33987, 2008.
15. 2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers. Prostaglandins Leukot Essent Fatty Acids 61: 65-82, 1999.
16. Prescott SM, McIntyre TM, Zimmerman GA. Events at the vascular wall: the molecular basis of inflammation. J Investig Med 49: 104-111, 2001.
17. Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 22: 727-733, 2002.
18. Pulichino AM, Rowland S, Wu T, Clark P, Xu D, Mathieu MC, Riendeau D, Audoly LP. Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther 319: 1043-1050, 2006.
19. 2 inhibitors. Prostaglandins Leukot Essent Fatty Acids 76: 205-212, 2007.
20. Riccioni G, Zanasi A, Vitulano N, Mancini B, D'Orazio N. Leukotrienes in atherosclerosis: new target insights and future therapy perspectives. Mediators Inflamm 2009: 737282, 2009.
21. Schoonderwoerd K, Stam H. Lipid metabolism of myocardial endothelial cells. Mol Cell Biochem 116: 171-179, 1992.
22. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 86: 49-86, 2000.
23. 2 enzymes: classification and characterization. Biochim Biophys Acta 1488: 1-19, 2000.
24. 2 by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols. Biochemistry 45: 1061-1073, 2006.
25. 2 contains eight ankyrin motifs. J Biol Chem 272: 8567-8575, 1997.
26. Tirziu D, Simons M. Endothelium-driven myocardial growth or nitric oxide at the crossroads. Trends Cardiovasc Med 18: 299-305, 2008.
27. Whatley RE, Zimmerman GA, McIntyre TM, Prescott SM. Lipid metabolism and signal transduction in endothelial cells. Prog Lipid Res 29: 45-63, 1990.
28. Wheeler-Jones CP. Regulation of endothelial prostacyclin synthesis by protease-activated receptors: mechanisms and significance. Pharmacol Rep 60: 109-118, 2008.
29. 2 leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res 120: 597-605, 2007.
30. White MC, McHowat J. The therapeutic potential of phospholipase A2 inhibitors in cardiovascular disease. Cardiovasc Hematol Agents Med Chem 1: 91-105, 2007.